Bausch + Lomb Corporation
BLCOBausch + Lomb Corporation is a global eye health company specializing in the development, manufacturing, and marketing of pharmaceutical and device-based products for eye care. Founded in 1853, the company offers a range of products including contact lenses, lens care solutions, ophthalmic pharmaceuticals, and surgical instruments, serving eye care professionals and consumers worldwide.
Company News
The global ophthalmology devices market is projected to grow from $56.61 billion in 2025 to $99.22 billion by 2030, with a CAGR of 11.9%. Key growth drivers include rising demand for minimally invasive surgeries, an aging population, increased eye disorders, and innovation in precision surgical tools. Leading companies include EssilorLuxottica, A...
Bausch + Lomb director Alfonso Eduardo purchased 4,300 shares for approximately $77,000 on March 2, 2026, at $17.90 per share. The company matched his purchase with 4,300 restricted stock units granted at no cost, vesting over three years. As a new director (joined January 1, 2026), Eduardo is working toward a mandatory $400,000 equity ownership ...
The Portnoy Law Firm has initiated a securities fraud investigation into Bausch + Lomb Corporation following significant stock price declines. The company's stock fell 9.8% on March 28, 2025, after disclosing increased reports of toxic anterior segment syndrome (TASS) related to enVista intraocular lenses, prompting a voluntary recall. A second d...
Bausch + Lomb reported $5.1 billion in annual revenue with 6% year-over-year growth, driven by contact lenses, consumer eye health products, and new pharmaceutical launches like MIEBO. Caspian Capital increased its stake by 1.35 million shares to $34.14 million, making it the firm's top holding at 22.6% of AUM. Despite underperforming the S&P 500...
The global ophthalmic drugs market is projected to reach US$41.88 billion in 2026 and grow at 7.9% CAGR through 2036, driven by biologic innovation, anti-VEGF therapies, AI-enabled diagnostics, and long-acting drug delivery systems. Key developments include expanded digital distribution channels and sustained-release implants reducing treatment b...
